Exploring Bispecific Approaches in Frontline Non-Hodgkin Lymphoma

Mitul Gandhi, MD, discusses data with epcoritamab in different racial subgroups of patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Phillips discusses updated data from the EPCORE NHL-1 trial investigating epcoritamab monotherapy in patients with relapsed/refractory LBCL.

Lorenzo Falchi, MD, expands on efficacy results from arms 6 and 7 of the phase 1b/2 EPCORE NHL-2 trial of epcoritamab in first-line follicular lymphoma.

Epcoritamab-based treatment yielded durable remissions in patients with follicular lymphoma, both as first-line induction and maintenance.

Epcoritamab plus R-CHOP delivered durable remissions beyond 3 years across high-risk subgroups of patients with newly diagnosed DLBCL.